367 related articles for article (PubMed ID: 24841351)
21. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
22. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
[TBL] [Abstract][Full Text] [Related]
24. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
[TBL] [Abstract][Full Text] [Related]
25. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
[TBL] [Abstract][Full Text] [Related]
26. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
27. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era.
Kibel AS; Ciezki JP; Klein EA; Reddy CA; Lubahn JD; Haslag-Minoff J; Deasy JO; Michalski JM; Kallogjeri D; Piccirillo JF; Rabah DM; Yu C; Kattan MW; Stephenson AJ
J Urol; 2012 Apr; 187(4):1259-65. PubMed ID: 22335870
[TBL] [Abstract][Full Text] [Related]
28. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
[TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
30. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.
Hayashi N; Osaka K; Muraoka K; Hasumi H; Makiyama K; Kondo K; Nakaigawa N; Yao M; Mukai Y; Sugiura M; Takano S; Ito E; Kaizu H; Koike I; Hata M; Taguri M; Miyoshi Y; Izumi K; Kawahara T; Uemura H
World J Urol; 2020 Oct; 38(10):2477-2484. PubMed ID: 31875247
[TBL] [Abstract][Full Text] [Related]
32. Race as an independent predictor of outcome after treatment for localized prostate cancer.
Sohayda CJ; Kupelian PA; Altsman KA; Klein EA
J Urol; 1999 Oct; 162(4):1331-6. PubMed ID: 10492191
[TBL] [Abstract][Full Text] [Related]
33. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
34. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.
Abdollah F; Suardi N; Cozzarini C; Gallina A; Capitanio U; Bianchi M; Sun M; Fossati N; Passoni NM; Fiorino C; Di Muzio N; Karakiewicz PI; Rigatti P; Montorsi F; Briganti A
Eur Urol; 2013 Jun; 63(6):998-1008. PubMed ID: 23122664
[TBL] [Abstract][Full Text] [Related]
35. The characteristics of bladder cancer after radiotherapy for prostate cancer.
Abern MR; Dude AM; Tsivian M; Coogan CL
Urol Oncol; 2013 Nov; 31(8):1628-34. PubMed ID: 22575239
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
Sheng W; Zhang H; Lu Y
Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
[TBL] [Abstract][Full Text] [Related]
38. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.
Shao YH; Kim S; Moore DF; Shih W; Lin Y; Stein M; Kim IY; Lu-Yao GL
Eur Urol; 2014 Apr; 65(4):693-700. PubMed ID: 23759328
[TBL] [Abstract][Full Text] [Related]
39. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
40. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
